0000000000878478

AUTHOR

Stefano L. Sensi

showing 6 related works from this author

A Critical Review of Alien Limb-Related Phenomena and Implications for Functional Magnetic Resonance Imaging Studies

2021

Consensus criteria on corticobasal degeneration (CBD) include alien limb (AL) phenomena. However, the gist of the behavioral features of AL is still “a matter of debate.” CBD-related AL has so far included the description of involuntary movements, frontal release phenomena (frontal AL), or asomatognosia (posterior or “real” AL). In this context, the most frequent symptoms are language and praxis deficits and cortical sensory misperception. However, asomatognosia requires, by definition, intact perception and cognition. Thus, to make a proper diagnosis of AL in the context of CBD, cognitive and language dysfunctions must be carefully verified and objectively assessed. We reviewed the current…

media_common.quotation_subjectContext (language use)ReviewAsomatognosiaPerceptionmedicineCorticobasal degenerationUtilization behaviorSet (psychology)RC346-429alien limbmedia_commondiagonistic dyspraxiamedicine.diagnostic_testneurodegenerationCognitioncorticobasal syndromemedicine.diseaseNeurologyalien handSettore MED/26 - NeurologiaNeurology (clinical)Neurology. Diseases of the nervous systemFunctional magnetic resonance imagingPsychologyCognitive psychologyFrontiers in Neurology
researchProduct

Posterior variant of alien limb syndrome with sudden clinical onset as self-hitting associated with thalamic stroke

2020

We present a case of sudden postischaemic onset of alien limb syndrome, with unintentional self-injury. Alien limb syndrome is an uncommon neurological disorder featured by uncontrolled and involuntary movements of a limb. Three variants of alien limb syndrome have been described: the anterior, featured by grasping of surrounding objects, the callosal, presenting with intermanual conflict, and the posterior, associated with involuntary levitation of the limb. Our patient suffered from an acute presentation of the posterior variant of the alien limb syndrome, resulting from an isolated thalamic stroke which was documented using 24-h computed tomography brain scan. Only one previous case of a…

medicine.medical_specialtyThalamic strokeAlien handNeurological disorderClinical onsetlcsh:RC346-42903 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationNeuroimagingmedicineSingle Case - General Neurology030212 general & internal medicineCerebrovascular diseaseStrokelcsh:Neurology. Diseases of the nervous systemInvoluntary movementbusiness.industryPosterior variant of alien limb syndromemedicine.diseaseSelf hittingbody regionsStrokeThalamic strokeSettore MED/26 - NeurologiaNeurology (clinical)Presentation (obstetrics)business030217 neurology & neurosurgery
researchProduct

A Stage-Based Approach to Therapy in Parkinson’s Disease

2019

Parkinson’s disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-phar…

0301 basic medicinemedicine.medical_specialtyParkinson's diseaseImpulse control disorderlcsh:QR1-502ReviewDiseasel-dopaBiochemistryREM sleep behavior disorderMotor symptomslcsh:MicrobiologyAntiparkinson Agentsnon-pharmacological therapy03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationmedicineHumansdopamine-agonistsApathyanticholinergicsResting tremorMolecular Biologyamantadinebusiness.industryAmantadineParkinson Diseasemonoamine oxidase inhibitorsmotor symptomsmedicine.diseasenon-motor symptoms030104 developmental biologyacetylcholinesterase inhibitorsParkinson’s disease<span style="font-variant: small-caps">l</span>-dopaSettore MED/26 - Neurologiamedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugBiomolecules
researchProduct

Data of safety in a single-center alemtuzumab treated population

2020

Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach.In the manuscript entitled “Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: report from a single Italian center” by di Ioia M. and collaborators, efficacy and safety data of alemtuzumab were evaluated in a real-world MS population. The aim of the article is to describe in detail the unexpected serious adverse events which occurred in this cohort during and after the administr…

Pediatricsmedicine.medical_specialtyPopulationlcsh:Computer applications to medicine. Medical informaticsSingle CenterMultiple sclerosis03 medical and health sciences0302 clinical medicinemedicinelcsh:Science (General)Adverse effecteducationAutoimmune hemolytic anemiaAlemtuzumabSecondary autoimmune disorders030304 developmental biology0303 health scienceseducation.field_of_studyMultidisciplinarybusiness.industryMultiple sclerosismedicine.diseasePancytopeniaAdverse eventsCohortlcsh:R858-859.7AlemtuzumabSettore MED/26 - NeurologiaAutoimmune hemolytic anemiaSafetybusiness030217 neurology & neurosurgerylcsh:Q1-390medicine.drugNeuroscience
researchProduct

Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center

2020

Abstract Background Alemtuzumab, is a compound approved for highly active MS, and, in Europe, employed after the use of other disease-modifying treatments (DMTs) with an escalation approach or used as a first therapeutic option. The occurrence of secondary autoimmune adverse events and or infections can differ depending on the employed approach. Objective To evaluate the efficacy and safety of alemtuzumab in real-world MS population that encompassed patients previously treated with other DMTs. Methods 35 patients, treated with alemtuzumab in a single MS Center, were followed for at least 36 months. The study investigated the prevalence of patients reaching the phase of the non-active diseas…

AdultMalemedicine.medical_specialtyMultiple SclerosisEfficacyPopulationDisease03 medical and health sciences0302 clinical medicineInternal medicinePost-hoc analysisOutcome Assessment Health CaremedicineHumansImmunologic Factors030212 general & internal medicineAdverse effecteducationAlemtuzumabeducation.field_of_studybusiness.industryMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseasePancytopeniaProgression-Free SurvivalNeurologyItalyAdverse eventsDisease ProgressionAlemtuzumabFemaleSettore MED/26 - NeurologiaNeurology (clinical)Autoimmune hemolytic anemiaSafetybusiness030217 neurology & neurosurgerymedicine.drugFollow-Up Studies
researchProduct

Interictal Heart Rate Variability Analysis Reveals Lateralization of Cardiac Autonomic Control in Temporal Lobe Epilepsy.

2020

International audience; Purpose: The temporal lobe, a critical hub for cognition, also plays a central role in the regulation of autonomic cardiovascular functions. Lesions in this area are usually associated with abnormalities in the regulation of heart rate (HR) and blood pressure (BP). The analysis of the heart rate variability (HRV) is useful to evaluate the cardiac parasympathetic nervous system activity. This study aims at comparing HRV changes occurring in two groups of patients suffering from Temporal Lobe Epilepsy (TLE). To that aim, we evaluated patients differentiated by the right or left location of the epileptic foci. Materials and Methods: Fifty-two adult patients with a diagn…

cardiovascular riskmedicine.medical_specialty030204 cardiovascular system & hematologySudden deathinterictal epileptic dischargebehavioral disciplines and activitiesinterictal epileptic dischargeslcsh:RC346-429Temporal lobe03 medical and health sciencesEpilepsy0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineHeart ratemedicineHeart rate variabilityIctallcsh:Neurology. Diseases of the nervous systemOriginal Researchbusiness.industrySeizure typesautonomic nervous systemheart rate variabilitytemporal lobe epilepsymedicine.diseasenervous system diseasesAutonomic nervous systemNeurologyCardiologySettore MED/26 - Neurologia[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Neurology (clinical)business030217 neurology & neurosurgeryFrontiers in neurology
researchProduct